METEORIC-HF: Omecamtiv mecarbil fails to improve exercise performance in HFrEF
WASHINGTON — In well-treated patients with chronic HF with reduced ejection fraction, omecamtiv mecarbil did not improve measures of exercise capacity over 20 weeks compared with placebo, researchers reported. Exercise is a “cardinal manifestation” of HF but is not improved by current medical therapies, G. Michael Felker, MD, MHS, professor of medicine at Duke Clinical Research